DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

—These investigators compared criteria from the two commonly used pathologic risk classification systems for endometrial carcinoma, assessed their concordance with molecular subtypes, and evaluated ...

Ovarian germ cell tumors: 11-year experience in a Mexican university hospital. Background: The diagnosis of endometrioid carcinomas, mixed type, is based upon presence of a serous component varying ...

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kathleen N. Moore, ...

The conversation often begins with subtle changes that women might initially dismiss as normal variations in their monthly cycle. Perhaps unusual bleeding between periods, or discharge that seems ...

Paraneoplastic syndromes are rarely seen in gynecological tumors especially in endometrial cancer. Early identification of paraneoplastic syndromes plays a significant role in the treatment and ...

"Endometrial hyperplasia and cancer are highly affected by obesity and lifestyle factors. Focusing on these factors in diverse communities will lead to our better understanding of these disparities.

Inside your pelvis is an organ that plays an important role in your period, ability to get pregnant, and carry a pregnancy. As with other parts of your body, sometimes cancer cells can grow there. The ...